BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 21549160)

  • 21. Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice.
    Mulvihill EE; Assini JM; Sutherland BG; DiMattia AS; Khami M; Koppes JB; Sawyez CG; Whitman SC; Huff MW
    Arterioscler Thromb Vasc Biol; 2010 Apr; 30(4):742-8. PubMed ID: 20110573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic implications of dietary trans-fatty acids.
    Dorfman SE; Laurent D; Gounarides JS; Li X; Mullarkey TL; Rocheford EC; Sari-Sarraf F; Hirsch EA; Hughes TE; Commerford SR
    Obesity (Silver Spring); 2009 Jun; 17(6):1200-7. PubMed ID: 19584878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A diet-induced hypercholesterolemic murine model to study atherogenesis without obesity and metabolic syndrome.
    Hartvigsen K; Binder CJ; Hansen LF; Rafia A; Juliano J; Hörkkö S; Steinberg D; Palinski W; Witztum JL; Li AC
    Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):878-85. PubMed ID: 17255537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse.
    Bahrami J; Longuet C; Baggio LL; Li K; Drucker DJ
    Gastroenterology; 2010 Sep; 139(3):857-68. PubMed ID: 20546737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice.
    Parthsarathy V; Hogg C; Flatt PR; O'Harte FPM
    Diabetes Obes Metab; 2018 Feb; 20(2):319-327. PubMed ID: 28730728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GLP-1 Elicits an Intrinsic Gut-Liver Metabolic Signal to Ameliorate Diet-Induced VLDL Overproduction and Insulin Resistance.
    Khound R; Taher J; Baker C; Adeli K; Su Q
    Arterioscler Thromb Vasc Biol; 2017 Dec; 37(12):2252-2259. PubMed ID: 29074588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GLP-1(28-36) improves β-cell mass and glucose disposal in streptozotocin-induced diabetic mice and activates cAMP/PKA/β-catenin signaling in β-cells in vitro.
    Shao W; Wang Z; Ip W; Chiang YT; Xiong X; Chai T; Xu C; Wang Q; Jin T
    Am J Physiol Endocrinol Metab; 2013 Jun; 304(12):E1263-72. PubMed ID: 23571712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous administration of multipotent stromal cells prevents the onset of non-alcoholic steatohepatitis in obese mice with metabolic syndrome.
    Ezquer M; Ezquer F; Ricca M; Allers C; Conget P
    J Hepatol; 2011 Nov; 55(5):1112-20. PubMed ID: 21356258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
    Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
    J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
    Ota T; Takamura T; Kurita S; Matsuzawa N; Kita Y; Uno M; Akahori H; Misu H; Sakurai M; Zen Y; Nakanuma Y; Kaneko S
    Gastroenterology; 2007 Jan; 132(1):282-93. PubMed ID: 17241878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tiliroside, a glycosidic flavonoid, ameliorates obesity-induced metabolic disorders via activation of adiponectin signaling followed by enhancement of fatty acid oxidation in liver and skeletal muscle in obese-diabetic mice.
    Goto T; Teraminami A; Lee JY; Ohyama K; Funakoshi K; Kim YI; Hirai S; Uemura T; Yu R; Takahashi N; Kawada T
    J Nutr Biochem; 2012 Jul; 23(7):768-76. PubMed ID: 21889885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome.
    Madsen AN; Hansen G; Paulsen SJ; Lykkegaard K; Tang-Christensen M; Hansen HS; Levin BE; Larsen PJ; Knudsen LB; Fosgerau K; Vrang N
    J Endocrinol; 2010 Sep; 206(3):287-96. PubMed ID: 20508079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel aminosterol reverses diabetes and fatty liver disease in obese mice.
    Takahashi N; Qi Y; Patel HR; Ahima RS
    J Hepatol; 2004 Sep; 41(3):391-8. PubMed ID: 15336441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome.
    Sasaki Y; Shimada T; Iizuka S; Suzuki W; Makihara H; Teraoka R; Tsuneyama K; Hokao R; Aburada M
    Eur J Pharmacol; 2011 Jul; 662(1-3):1-8. PubMed ID: 21549692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Actions of incretin metabolites on locomotor activity, cognitive function and in vivo hippocampal synaptic plasticity in high fat fed mice.
    Porter D; Faivre E; Flatt PR; Hölscher C; Gault VA
    Peptides; 2012 May; 35(1):1-8. PubMed ID: 22465882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice.
    Parlevliet ET; Schröder-van der Elst JP; Corssmit EP; Picha K; O'Neil K; Stojanovic-Susulic V; Ort T; Havekes LM; Romijn JA; Pijl H
    J Pharmacol Exp Ther; 2009 Jan; 328(1):240-8. PubMed ID: 18849357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of aldosterone on diet-induced fatty liver formation in male C57BL/6 mice: comparison of adrenalectomy and mineralocorticoid receptor blocker.
    Gamliel-Lazarovich A; Raz-Pasteur A; Coleman R; Keidar S
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1086-92. PubMed ID: 23524523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular hydrogen improves obesity and diabetes by inducing hepatic FGF21 and stimulating energy metabolism in db/db mice.
    Kamimura N; Nishimaki K; Ohsawa I; Ohta S
    Obesity (Silver Spring); 2011 Jul; 19(7):1396-403. PubMed ID: 21293445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice.
    Patel V; Joharapurkar A; Dhanesha N; Kshirsagar S; Patel K; Bahekar R; Shah G; Jain M
    Can J Physiol Pharmacol; 2013 Dec; 91(12):1009-15. PubMed ID: 24289070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance.
    Porter DW; Kerr BD; Flatt PR; Holscher C; Gault VA
    Diabetes Obes Metab; 2010 Oct; 12(10):891-9. PubMed ID: 20920042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.